<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337931</url>
  </required_header>
  <id_info>
    <org_study_id>APX005M-010</org_study_id>
    <nct_id>NCT04337931</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate APX005M in Subjects With Unresectable or Metastatic Melanoma</brief_title>
  <official_title>A Phase II Multicenter, Open-label Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M With or Without Stereotactic Body Radiation in Adults With Unresectable or Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apexigen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apexigen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, Phase 2 study, with 3 parallel cohorts. The aim of the&#xD;
      study is to evaluate the efficacy of APX005M administered at 2 different schedules to adult&#xD;
      subjects with unresectable or metastatic melanoma. Subjects who have not received prior&#xD;
      immunotherapy will be alternately assigned to 1 of 2 cohorts (2 different APX005M&#xD;
      administration schedules) as long as both are open. Subjects who have failed approved&#xD;
      immunotherapy regimens will be assigned to a 3rd cohort of APX005M in combination with&#xD;
      radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">November 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>CR + PR (RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of AEs and specific laboratory abnormalities</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR by iRECIST</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Unresectable Melanoma</condition>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APX005M every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APX005M every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APX005M every 2 weeks plus radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX005M</intervention_name>
    <description>2 different administration schedules per treatment cycle</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          -  Histologically or cytologically confirmed unresectable or metastatic melanom&#xD;
&#xD;
          -  Measurable disease by RECIST 1.1&#xD;
&#xD;
          -  Subjects with BRAF activating mutation must have received a BRAF inhibitor and/or MEK&#xD;
             inhibitor regimen prior to study entry&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Use of systemic corticosteroids or other systemic immunosuppressive drugs within the&#xD;
             28 days prior to first dose of investigational product (except inhaled&#xD;
             corticosteroids) History of allogeneic bone marrow transplantation&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in past 2 years (i.e.&#xD;
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs)&#xD;
&#xD;
          -  History of (non-infectious) pneumonitis that required corticosteroids or current&#xD;
             pneumonitis&#xD;
&#xD;
          -  History of interstitial lung disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie National Research Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Rutkowski</last_name>
      <phone>48 22 546 21 03</phone>
      <email>rutkowskip@coi.waw.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María González Cao</last_name>
      <phone>9354 0135</phone>
      <email>mgonzalezcao@oncorosell.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Muñoz</last_name>
      <phone>+34 274 60 00</phone>
      <phone_ext>4350</phone_ext>
      <email>emunoz@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delvys Rodríguez</last_name>
      <phone>661 672 235</phone>
      <email>delvysra@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Cerezuela</last_name>
      <phone>666496774</phone>
      <email>pcerezuelaf@seom.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. R. U. de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Berciano, MD</last_name>
      <phone>34 951 291 425</phone>
      <email>migueberci@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Esperanza Rodriguez Ruiz, MD</last_name>
      <phone>34 948 255 400</phone>
      <email>mrruiz@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués De Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Almudena Garcia</last_name>
      <phone>34 942 20 25 25</phone>
      <email>almudena.garcia@scsalud.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. U. de Canarias</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juana Oramas</last_name>
      <phone>922 678 204</phone>
      <email>juanaoramas@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano De Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª José de Juan, MD</last_name>
      <phone>34 961 114 008</phone>
      <email>mjuanfi81@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. U. Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Ochenduszko, MD</last_name>
      <phone>34 963 189 169</phone>
      <email>sebaochenduszko@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C. H. U.de Vigo</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MªJosé Villanueva, MD</last_name>
      <phone>34 986 825 830</phone>
      <email>maria.jose.villanueva.silva@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. U. Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Puertolas, MD</last_name>
      <phone>34 976 359 268</phone>
      <email>tjpuertolas@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

